Renal Disease With Edema — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for renal disease with edema. 4 active patents protecting 1 drugs from 0+ originators. First major cliff: 2040. Daily refresh.

1
Approved drugs
4
Active US patents
70/100
Avg vulnerability
—
Annual revenue covered

Originators in Renal Disease With Edema

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating renal disease with edema. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Bumex
BUMETANIDE
 — 4 70 — 2040-12-04

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12329731 Bumex method of use 75 2040-12-04
11260038 Bumex method of use 75 2040-12-04
12558330 Bumex method of use 75 2045-05-14
11123319 Bumex formulation 55 2040-12-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11123319 Bumex formulation 55 2040-12-04
12558330 Bumex method of use 75 2045-05-14
12329731 Bumex method of use 75 2040-12-04
11260038 Bumex method of use 75 2040-12-04

Related